Bleomycin versus Doxycycline: A Patient-Oriented Approach to Pleurodesis

Abstract

Get full access to this article

View all access options for this article.

References

Fingar

. Sclerosing agents used to control malignant pleural effusions. Hasp Pharm 1992; 27: 622–8.

Wertyschyn

. Sclerosing agents used in malignant pleural effusions. P&T 1992;(Aug):1287.

Gericke

. Doxycycline as a sclerosing agent. Ann Pharmacother 1992; 26: 648–9.

Kitamura

Sugiyama

Izumi

Hayashi

Kosaka

. Intrapleural doxycycline for control of malignant pleural effusion. Curr Ther Res 1981; 30: 515–21.

Mansson

. Treatment of malignant pleural effusion with doxycycline. Scand J Infect Dis 1988; 53 (suppl): 29–34.

Ruckdeschel

Moores

Lee

Einhorn

Mandelbaum

Koeller

Intrapleural therapy for malignant pleural effusions: a randomized comparison of bleomycin and tetracycline. Chest 1991; 100: 1528–35.

Paladine

Cunningham

Sponzo

Donavan

Olson

Horton

. Intracavitary bleomycin in the management of malignant effusions. Cancer 1976; 38: 1903–78.

Bitran

Brown

Desser

Kozloff

Shapiro

Billings

. Intracavitary bleomycin for the control of malignant effusions. J Surg Oncol 1981; 16: 273–7.

Ostrowski

. An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavitary bleomycin. Cancer 1986; 57: 721–7.

10.

Ostrowski

Halsall

. Intracavitary bleomycin in the management of malignant effusions: a multicenter study. Cancer Treat Rep 1982; 66: 1903–7.

11.

Siegel

Schiffman

. Systemic toxicity following intracavitary administration of bleomycin. Chest 1990; 98: 507.

12.

Sifton

, ed. 1992 Drug topics red book. 96th ed. Montvale, NJ: Medical Economics Data.